Burden of breast cancer with brain metastasis: a French national hospital database analysis

Benjamin, L; Cotté, François-Emery; Mercier, F.; Vainchtock, A.; Vidal-Trecan, Gwenaëlle; Durand-Zaleski, Isabelle

doi:10.3111/13696998.2012.662924

Cited by 8 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brain metastasis is a major complication of breast cancer that significantly impairs patients’ survival and quality of life [1], [2]. It occurs in 3–6% of all breast cancer patients [3], and the risk can increase to 10–43% in patients with metastatic breast cancer [4]–[6].…”

Section: Introductionmentioning

confidence: 99%

Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients

Hung

Liu

Shiau

et al. 2014

PLoS ONEHas correction 2014-6-13

View full text Add to dashboard Cite

BackgroundBrain metastasis is a major complication of breast cancer. This study aimed to analyze the effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients.Patients and MethodsWe identified subtypes of invasive ductal carcinoma of the breast by determining estrogen receptor, progesterone receptor and HER2 status. Time to brain metastasis according to age and cancer subtype was analyzed by Cox proportional hazard analysis.ResultsOf the 2248 eligible patients, 164 (7.3%) developed brain metastasis over a median follow-up of 54.2 months. Age 35 or younger, HER2-enriched subtype, and triple-negative breast cancer were significant risk factors of brain metastasis. Among patients aged 35 or younger, the risk of brain metastasis was independent of biological subtype (P = 0.507). Among patients aged 36–59 or >60 years, those with triple-negative or HER2-enriched subtypes had consistently increased risk of brain metastasis, as compared with those with luminal A tumors. Patients with luminal B tumors had higher risk of brain metastasis than luminal A only in patients >60 years.ConclusionsBreast cancer subtypes are associated with differing risks of brain metastasis among different age groups. Patients age 35 or younger are particularly at risk of brain metastasis independent of biological subtype.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients

Hung

Liu

Shiau

et al. 2014

PLoS ONEHas correction 2014-6-13

View full text Add to dashboard Cite

show abstract

“…So long as they are identified at such a late stage, any treatment benefits will continue to be incremental [ 119 ] and yet, currently, diagnostic imaging is routinely performed on symptomatic patients and not for screening purposes. The risk of BM is increasing with improving systemic disease control [ 2 , 113 , 118 , 120 , 121 ], indicating that micrometastases can develop into clinically significant BM if given time and opportunity. Critically, while 14%–15% of breast cancer patients develop symptomatic BM, evidence suggests they are actually far more prevalent—in a meta-analysis of CT/MRI data acquired to satisfy eligibility criteria for anti-angiogenic therapy trials in the late 1990s, Miller et al found a roughly equal proportion of BC patients (~15%) had clinically occult BM [ 122 ].…”

Section: Factors Underlying the Recalcitrant Behaviour Of Brain Mementioning

confidence: 99%

Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context

Saunus

Reed

Lim

et al. 2017

IJMS

View full text Add to dashboard Cite

Brain metastases are highly-evolved manifestations of breast cancer arising in a unique microenvironment, giving them exceptional adaptability in the face of new extrinsic pressures. The incidence is rising in line with population ageing, and use of newer therapies that stabilise metastatic disease burden with variable efficacy throughout the body. Historically, there has been a widely-held view that brain metastases do not respond to circulating therapeutics because the blood-brain-barrier (BBB) restricts their uptake. However, emerging data are beginning to paint a more complex picture where the brain acts as a sanctuary for dormant, subclinical proliferations that are initially protected by the BBB, but then exposed to dynamic selection pressures as tumours mature and vascular permeability increases. Here, we review key experimental approaches and landmark studies that have charted the genomic landscape of breast cancer brain metastases. These findings are contextualised with the factors impacting on clonal outgrowth in the brain: intrinsic breast tumour cell capabilities required for brain metastatic fitness, and the neural niche, which is initially hostile to invading cells but then engineered into a tumour-support vehicle by the successful minority. We also discuss how late detection, abnormal vascular perfusion and interstitial fluid dynamics underpin the recalcitrant clinical behaviour of brain metastases, and outline active clinical trials in the context of precision management.

show abstract

“…The management of brain metastases (BMs) is a critical area of unmet need affecting over 100 000 cancer patients annually in the USA at a cost of more than US$ 3 billion, largely for palliative care . The incidence varies between primary cancer types (10–40% overall), being highest for lung, breast, renal cancers and melanoma .…”

Section: Introductionmentioning

confidence: 99%

Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance

et al. 2015

View full text Add to dashboard Cite

Treatment options for patients with brain metastases (BMs) have limited efficacy and the mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our understanding of mechanisms underpinning metastatic outgrowth in the brain is limited. To address these deficiencies, we investigated the genomic and transcriptomic landscapes of 36 BMs from breast, lung, melanoma and oesophageal cancers, using DNA copy-number analysis and exome-and RNA-sequencing. The key findings were as follows.

show abstract

Burden of breast cancer with brain metastasis: a French national hospital database analysis

Cited by 8 publications

References 31 publications

Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients

Effect of Age and Biological Subtype on the Risk and Timing of Brain Metastasis in Breast Cancer Patients

Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context

Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance

Contact Info

Product

Resources

About